FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hilary Calvert

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Christophe Massard; Mariano Siguero; Jean Charles Soria; Peter Stephens; Vicente Alfaro; Nadia Amellal; Jean Pierre Armand; Ratislav Bahleda; Hilary Calvert; Cinthya Coronado; Yvette Drew; Carlos Fernández-Teruel; Carmen Kahatt; Jane Margetts; Ruth Plummer
Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Christophe Massard; Mariano Siguero; Jean Charles Soria; Peter Stevens; Vicente Alfaro; Nadia Amellal; Jean Pierre Armand; Ratislav Bahleda; Hilary Calvert; Cinthya Coronado; Yvette Drew; Carlos Fernández-Teruel; Carmen Kahatt; Jane Margetts; Ruth Plummer
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Ruth Plummer; Lucy Scott; Neil Steven; Diane Wang; Richard H Wilson; Nicola Curtin; Raz Dewji; Jorge Gallo; Paul Lorigan; Mark R Middleton; Evan Mulligan; Antonello Abbattista; Hilary Calvert
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hilary Calvert (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Christophe Massard; Mariano Siguero; Jean Charles Soria; Peter Stephens; Vicente Alfaro; Nadia Amellal; Jean Pierre Armand; Ratislav Bahleda; Hilary Calvert; Cinthya Coronado; Yvette Drew; Carlos Fernández-Teruel; Carmen Kahatt; Jane Margetts; Ruth Plummer
Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Investigational new drugs 2013;31(3):799.
2013: Christophe Massard; Mariano Siguero; Jean Charles Soria; Peter Stevens; Vicente Alfaro; Nadia Amellal; Jean Pierre Armand; Ratislav Bahleda; Hilary Calvert; Cinthya Coronado; Yvette Drew; Carlos Fernández-Teruel; Carmen Kahatt; Jane Margetts; Ruth Plummer
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Investigational new drugs 2013;31(3):623-30.
2013: Ruth Plummer; Lucy Scott; Neil Steven; Diane Wang; Richard H Wilson; Nicola Curtin; Raz Dewji; Jorge Gallo; Paul Lorigan; Mark R Middleton; Evan Mulligan; Antonello Abbattista; Hilary Calvert
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Cancer chemotherapy and pharmacology 2013;71(5):1191-9.
2011: Hilary Calvert; A Azzariti
The clinical development of inhibitors of poly(ADP-ribose) polymerase.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22 Suppl 1():i53-9.
2010: David Boss; Gary K Schwartz; M R Middleton; D D Amakye; H Swaisland; R S Midgley; M Ranson; S Danson; Hilary Calvert; R Plummer; C Morris; Richard Carvajal; L R Chirieac; J H M Schellens; G I Shapiro
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(4):884-94.
2009: Ruth Plummer; Laura Vidal; Melanie Griffin; Mark Lesley; Johann S de Bono; Sally Coulthard; Julieann Sludden; Lillian L Siu; Eric X Chen; Amit Oza; Gregory K Reid; A Robert McLeod; Jeffrey M Besterman; Chooi Lee; Ian Judson; Hilary Calvert; Alan V Boddy
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3177-83.
2008: Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola J Curtin; Alan V Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7917-23.
2008: Yvette Drew; Hilary Calvert
The potential of PARP inhibitors in genetic breast and ovarian cancers.
Annals of the New York Academy of Sciences 2008;1138():136-45.
2007: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nicholas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Hilary Calvert; Alan V Boddy; Harry Hollema; Regine Féty; Wjf J F Van der Vijgh; Georg Hempel; Etienne Chatelut; Mats Karlsson; Justin Wilkins; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6410-8.
2007: Elizabeth Ruth Plummer; Hilary Calvert
Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6252-6.
2007: Ruth Plummer; Gerhardt Attard; Simon Pacey; Louise Li; Albiruni Razak; Rebecca Perrett; Mary Barrett; Ian Judson; Stan Kaye; Norma Lynn Fox; Wendy Halpern; Alfred Corey; Hilary Calvert; Johann S de Bono
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6187-94.
2004: andrew bottomley; Laura Biganzoli; Tanja Cufer; Robert E Coleman; Corneel Coens; Fabio Efficace; Hilary Calvert; Teresa Gamucci; Chris Twelves; Pierre Fargeot; Martine Piccart
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2576-86.
2004: Fabio Efficace; Laura Biganzoli; Martine Piccart; Corneel Coens; Kristel van Steen; Tanja Cufer; R E Coleman; Hilary Calvert; Teresa Gamucci; Chris Twelves; Pierre Fargeot; andrew bottomley
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(7):1021-30.
2004: Nicola J Curtin; Lan-Zhen Wang; Anthie Yiakouvaki; Suzanne Kyle; Christine A Arris; Stacie S Canan Koch; Stephen E Webber; Barbara W Durkacz; Hilary Calvert; Zdenek Hostomsky; David R Newell
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):881-9.
2003: Christian Dittrich; Herlinde Dumez; Hilary Calvert; Axel R Hanauske; Marije Faber; Jantien Wanders; Murray Yule; Miroslav Ravic; Pierre Fumoleau
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5195-204.
2003: Hilary Calvert
Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
Seminars in oncology 2003;30(2 Suppl 3):2-5.
2003: Ruth Plummer; Charlotte Rees; Andrew Hughes; Philip Beale; Martin Highley; Jose Manuel Trigo; Sathyarathnarn Gokul; Ian Judson; Hilary Calvert; Ann L Jackman; Fraser Mitchell; Robert Smith; Edwin Douglass
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1313-22.
2002: Hilary Calvert; Duncan I Jodrell; James Cassidy; Adrian L Harris
Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.
BMJ (Clinical research ed.) 2002;325(7375):1302; author reply 1302.
2002: Ruth Plummer; Michele Ghielmini; Paula Calvert; Maurizio Voi; Josette Renard; Gilles Gallant; Elora Gupta; Hilary Calvert; Cristiana Sessa
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2788-97.
2002: Andy Hughes; Paula Calvert; Ashraf Azzabi; Ruth Plummer; Rob Johnson; Jim Rusthoven; Melanie Griffin; Kevin Fishwick; Alan V Boddy; Mark Verrill; Hilary Calvert
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3533-44.
2002: Hilary Calvert; Paul A Bunn
Future directions in the development of pemetrexed.
Seminars in oncology 2002;29(2 Suppl 5):54-61.
2002: Hilary Calvert
Folate status and the safety profile of antifolates.
Seminars in oncology 2002;29(2 Suppl 5):3-7.
2002: J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; Per Dombernowsky; Robert Paridaens; A T van Oosterom; Jaap Verweij; Walter J Loos; Hilary Calvert; Nicholas Pavlidis; H Cortes-Funes; Jantien Wanders; MW Roelvink; Cristiana Sessa; K Selinger; Paul Wissel; Teresa Gamucci; Axel R Hanauske
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Investigational new drugs 2002;20(1):83-93.
2001: J Smyth; M E Boneterre; J Schellens; Hilary Calvert; GA Greim; Jantien Wanders; Axel R Hanauske
Activity of the dolastatin analogue, LU103793, in malignant melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(4):509-11.
2000: Nicholas Pavlidis; Steinar Aamdal; A Awada; Hilary Calvert; Pierre Fumoleau; Roberto Sorio; C Punt; J Verweij; Allan van Oosterom; Rudolf Morant; Jantien Wanders; Axel R Hanauske
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Cancer chemotherapy and pharmacology 2000;46(2):167-71.
1999: Hilary Calvert
MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions.
Seminars in oncology 1999;26(2 Suppl 6):105-8.
1999: Hilary Calvert
An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
Seminars in oncology 1999;26(2 Suppl 6):3-10.
1993: Hilary Calvert; I Judson; W J van der Vijgh
Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.
Cancer surveys 1993;17():189-217.